)
Summary of poster presentation:
- TSND-201 demonstrated rapid, robust, and consistent improvements across each PTSD symptom domain (Intrusion, Avoidance, Cognition and Mood, Arousal and Reactivity).
- Rapid and durable improvement on anxiety symptoms occurred concurrently with PTSD symptom improvement.
- TSND-201 was generally safe and well tolerated; the most common adverse events (AEs) were headache and decreased appetite.
- Randomized, placebo-controlled study is ongoing, with results expected in Q2 2025.
